Analyzing Spectral AI (NASDAQ:MDAI) and Sartorius (OTCMKTS:SARTF)

Spectral AI (NASDAQ:MDAI) and Sartorius (OTCMKTS:SARTF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Spectral AI and Sartorius, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1	0	1	0	2.00
Sartorius	0	0	0	1	4.00

Spectral AI presently has a consensus price target of $3.00, suggesting a potential upside of 58.73%. Given Spectral AI’s higher possible upside, analysts clearly believe Spectral AI is more favorable than Sartorius.

Profitability

This table compares Spectral AI and Sartorius’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-41.11%	N/A	-35.64%
Sartorius	3.82%	8.19%	3.15%

Earnings and Valuation

This table compares Spectral AI and Sartorius”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65 million	3.06	-$7.57 million	($0.31)	-6.10
Sartorius	$3.66 billion	2.12	$90.90 million	$2.15	105.27

Sartorius has higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Sartorius, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Spectral AI has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Sartorius has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Sartorius beats Spectral AI on 10 of the 15 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Sartorius

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.